Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis

被引:15
作者
de Andrade, Joao A. [1 ]
Neely, Megan L. [2 ,3 ]
Hellkamp, Anne S. [2 ,3 ]
Culver, Daniel A. [4 ]
Kim, Hyun J. [5 ]
Liesching, Timothy [6 ]
Lobo, Leonard J. [7 ]
Ramaswamy, Murali [8 ]
Safdar, Zeenat [9 ]
Bender, Shaun [10 ]
Conoscenti, Craig S. [10 ]
Leonard, Thomas B. [10 ]
Palmer, Scott M. [2 ,3 ]
Snyder, Laurie D. [2 ,3 ]
机构
[1] Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA
[2] Duke Clin Res Inst, Durham, NC USA
[3] Duke Univ Med Ctr, Durham, NC USA
[4] Cleveland Clin, Cleveland Hts, OH USA
[5] Univ Minnesota, Minneapolis, MN USA
[6] Lahey Hosp & Med Ctr, Burlington, MA USA
[7] UNC Sch Med, Chapel Hill, NC USA
[8] PulmonIx LLC Cone Hlth, Greensboro, NC USA
[9] Houston Methodist Hosp, Houston Methodist Lung Ctr, Weill Cornell Med, Houston, TX USA
[10] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
关键词
Idiopathic pulmonary fibrosis; Intersti-tial fibrosis; Mortality; Disease progression; ACUTE EXACERBATION; PIRFENIDONE; NINTEDANIB; MORTALITY; EFFICACY;
D O I
10.1016/j.clinthera.2023.03.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: Real-world studies have reported reduced mortality in patients with idiopathic pulmonary fibro-sis (IPF) treated with antifibrotic therapy; however, the initiation or discontinuation of therapy during these studies may have introduced bias. This study investigated the effect of antifibrotic therapy on mortality and other outcomes in patients with IPF using causal inference methodology. Methods: Data from a multicenter US registry of patients with IPF were used to assess the effect of antifibrotic therapy (nintedanib or pirfenidone) on death, death or lung transplant, respiratory-related hospitalization, and acute worsening of IPF (defined as any health care encounter deemed due to acute worsening of IPF). This study used the Gran method, which accounts for differences in patient characteristics and for treatment initiations and discontinuations during follow-up. The analysis cohort was limited to patients who started antifibrotic therapy on or after the day of enrollment or had never taken it.Findings: Among the 499 patients analyzed, 352 (70.5%) received antifibrotic therapy. Estimated event rates of death at 1 year were 6.6% (95% CI, 6.1-7.1)for treated patients and 10.2% (95% CI, 9.5-10.9) for control patients. There was a numerical reduction in the risk of death (hazard ratio [HR], 0.53; 95% CI, 0.28-1.03; P = 0.060) but numerical increases in risks of respiratory-related hospitalization (HR, 1.88; 95% CI, 0.90-3.92; P = 0.091) and acute worsening of IPF (HR, 1.71; 95% CI, 0.36-8.09; P = 0.496) in treated versus control patients.Implications: Analyses based on causal inference methodology suggest that patients with IPF who receive antifibrotic therapy have improved survival. (Clin Ther. 2023;45:306-315.) (c) 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )
引用
收藏
页码:306 / 315
页数:10
相关论文
共 37 条
[1]   In-hospital mortality trends among patients with idiopathic pulmonary fibrosis in the United States between 2013-2017: a comparison of academic and non-academic programs [J].
Alqalyoobi, Shehabaldin ;
Fernandez Perez, Evans R. ;
Oldham, Justin M. .
BMC PULMONARY MEDICINE, 2020, 20 (01)
[2]   An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies [J].
Austin, Peter C. .
MULTIVARIATE BEHAVIORAL RESEARCH, 2011, 46 (03) :399-424
[3]   Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry [J].
Behr, Juergen ;
Prasse, Antje ;
Wirtz, Hubert ;
Koschel, Dirk ;
Pittrow, David ;
Held, Matthias ;
Klotsche, Jens ;
Andreas, Stefan ;
Claussen, Martin ;
Grohe, Christian ;
Wilkens, Henrike ;
Hagmeyer, Lars ;
Skowasch, Dirk ;
Meyer, Joachim F. ;
Kirschner, Joachim ;
Glaeser, Sven ;
Kahn, Nicolas ;
Welte, Tobias ;
Neurohr, Claus ;
Schwaiblmair, Martin ;
Bahmer, Thomas ;
Oqueka, Tim ;
Frankenberger, Marion ;
Kreuter, Michael .
EUROPEAN RESPIRATORY JOURNAL, 2020, 56 (02)
[4]   Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis [J].
Collard, Harold R. ;
Richeldi, Luca ;
Kim, Dong Soon ;
Taniguchi, Hiroyuki ;
Tschoepe, Inga ;
Luisetti, Maurizio ;
Roman, Jesse ;
Tino, Gregory ;
Schlenker-Herceg, Rozsa ;
Hallmann, Christoph ;
du Bois, Roland M. .
EUROPEAN RESPIRATORY JOURNAL, 2017, 49 (05)
[5]   Acute Exacerbation of Idiopathic Pulmonary Fibrosis An International Working Group Report [J].
Collard, Harold R. ;
Ryerson, Christopher J. ;
Corte, Tamera J. ;
Jenkins, Gisli ;
Kondoh, Yasuhiro ;
Lederer, David J. ;
Lee, Joyce S. ;
Maher, Toby M. ;
Wells, Athol U. ;
Antoniou, Katerina M. ;
Behr, Juergen ;
Brown, Kevin K. ;
Cottin, Vincent ;
Flaherty, Kevin R. ;
Fukuoka, Junya ;
Hansell, David M. ;
Johkoh, Takeshi ;
Kaminski, Naftali ;
Kim, Dong Soon ;
Kolb, Martin ;
Lynch, David A. ;
Myers, Jeffrey L. ;
Raghu, Ganesh ;
Richeldi, Luca ;
Taniguchi, Hiroyuki ;
Martinez, Fernando J. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 194 (03) :265-275
[6]   Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis [J].
Dempsey, Timothy M. ;
Sangaralingham, Lindsey R. ;
Yao, Xiaoxi ;
Sanghavi, Darshak ;
Shah, Nilay D. ;
Limper, Andrew H. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 200 (02) :168-174
[7]   EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis [J].
Doubkova, Martina ;
Svancara, Jan ;
Svoboda, Michal ;
Sterclova, Martina ;
Bartos, Vladimir ;
Plackova, Martina ;
Lacina, Ladislav ;
Zurkova, Monika ;
Binkova, Ilona ;
Bittenglova, Radka ;
Lost'akova, Vladimira ;
Merta, Zdenek ;
Siskova, Lenka ;
Tyl, Richard ;
Lisa, Pavlina ;
Suldova, Hana ;
Petrik, Frantisek ;
Psikalova, Jana ;
Rihak, Vladimir ;
Snizek, Tomas ;
Reiterer, Pavel ;
Homolka, Jiri ;
Musilova, Pavlina ;
Lnenicka, Jaroslav ;
Paluch, Peter ;
Hrdina, Roman ;
Kralova, Renata ;
Hortvikova, Hana ;
Strenkova, Jana ;
Vasakova, Martina .
CLINICAL RESPIRATORY JOURNAL, 2018, 12 (04) :1526-1535
[8]   A retrospective study of in-hospital mortality in patients with idiopathic pulmonary fibrosis between 2015 and 2018 [J].
Durheim, Michael T. ;
Judy, Jennifer ;
Bender, Shaun ;
Neely, Megan L. ;
Baumer, Dorothy ;
Robinson, Scott B. ;
Conoscenti, Craig S. ;
Leonard, Thomas B. ;
Lazarus, Howard M. ;
Palmer, Scott M. .
MEDICINE, 2020, 99 (47) :e23143
[9]   Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial [J].
Flaherty, Kevin R. ;
Wells, Athol U. ;
Cottin, Vincent ;
Devaraj, Anand ;
Inoue, Yoshikazu ;
Richeldi, Luca ;
Walsh, Simon L. F. ;
Kolb, Martin ;
Koschel, Dirk ;
Moua, Teng ;
Stowasser, Susanne ;
Goeldner, Rainer-Georg ;
Schlenker-Herceg, Rozsa ;
Brown, Kevin K. .
EUROPEAN RESPIRATORY JOURNAL, 2022, 59 (03)
[10]   Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry [J].
Gao, Jing ;
Kalafatis, Dimitrios ;
Carlson, Lisa ;
Pesonen, Ida H. A. ;
Li, Chuan-Xing ;
Wheelock, Asa ;
Magnusson, Jesper M. ;
Skold, C. Magnus .
RESPIRATORY RESEARCH, 2021, 22 (01)